Notice Received Under Section 249D of the Corporations Act
December 01 2017 - 5:00AM
Genetic Technologies Limited (ASX:GTG) (NASDAQ:GENE) (“Company”),
advises that on 29 November it received a notice under Section 249D
of the Corporations Act 2001
(Section 249D Notice)
requesting the Company call and arrange to hold a meeting of the
members of the Company.
The Section 249D Notice was received from;
- Antanas Guoga,
- Ugnius Simelionis,
- Security and Equity Resources Limited,
- SH Rayburn Nominees Pty Ltd ATF SH Rayburn Super Fund,
- Irwin Biotech Nominees Pty Ltd ATF BIOA Trust,
- MJGD Nominees Pty Ltd ATF BSMI Trust, and
- Samuel Lee
who claim to hold approximately 5.5% of the
issued shares of the Company. The Section 249D Notice seeks the
removal of Dr Malcolm R. Brandon, Mr Grahame Leonard and Mr
Eutillio Buccilli as directors of the Company, and the appointment
of Mr Samuel Xue Lee, Mr Peter Irwin Rubenstein and Mr Jerzy
Muchnicki as directors of the Company
The Company is seeking legal advice as to the
validity of the Section 249D Notice and will keep the market
informed of all material developments concerning the
requisition.______________________________________________
FOR FURTHER INFORMATION PLEASE CONTACT
Mr. Eutillio Buccilli
Executive
Director & Chief Executive Officer
Genetic
Technologies
Limited
+ 61 3 8412 7050
Jason Wong (USA) Blueprint Life
Science Group+ 1 (415) 375 3340, Ext. 4
About Genetic Technologies
LimitedGenetic Technologies is a molecular diagnostics
company that offers cancer predictive testing and assessment tools
to help physicians proactively manage patient health. The Company’s
lead product, BREVAGenplus®, is a clinically validated risk
assessment test for non-hereditary breast cancer and is first in
its class. BREVAGenplus is designed to facilitate better
informed decisions about breast cancer screening and preventive
treatment plans, and is directed towards women aged 35 years or
above, who have not had breast cancer and have one or more risk
factors for developing breast cancer.
The Company markets BREVAGenplus, through its
U.S. subsidiary Phenogen Sciences Inc., to healthcare professionals
in comprehensive breast health care and imaging centres, as well as
to obstetricians/gynaecologists (OBGYNs) and breast cancer risk
assessment specialists (such as breast surgeons). For more
information, please visit www.brevagenplus.com and
www.phenogensciences.com.
Genetic Technologies is developing a pipeline of
risk assessment products including a novel colorectal cancer (CRC)
test. For more information, please visit www.gtgcorporate.com
Safe Harbor Statement
Any statements in this press release that relate
to the Company's expectations are forward-looking statements,
within the meaning of the Private Securities Litigation Reform Act.
The Private Securities Litigation Reform Act of 1995 (PSLRA)
implemented several significant substantive changes affecting
certain cases brought under the federal securities laws, including
changes related to pleading, discovery, liability, class
representation and awards fees. Since this information may involve
risks and uncertainties and are subject to change at any time, the
Company's actual results may differ materially from expected
results. Additional risks associated with Genetic Technologies'
business can be found in its periodic filings with the SEC.
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Sep 2023 to Sep 2024